Clinical Trials Directory

Trials / Completed

CompletedNCT00586963

Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis

How Does Proton Pump Inhibitor Therapy Impact Quality of Life in Patients Newly Diagnosed With Erosive Reflux Esophagitis?

Status
Completed
Phase
Study type
Observational
Enrollment
65 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is being done to for two reasons: * To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly. * To learn about the quality of life changes (good and bad) you may experience with this medication.

Detailed description

The plan is to have 50 people take part in this study at Mayo Clinic Rochester. This research study is looking at people who have a new condition called erosive reflux esophagitis. Esophagitis is defined as mucosal damage produced by the abnormal reflux of gastric contents into the esophagus. Acid reflux, over time, can wear away or erode the lining of your esophagus. This condition is called erosive esophagitis. The treating physician may start you on prescription strength acid reducing group of medications called Proton Pump Inhibitors (PPI). PPI medications can provide 24-hour relief from your painful heartburn symptoms and it can help you heal the erosions in the esophagus that acid reflux may cause.

Conditions

Timeline

Start date
2008-01-01
Primary completion
2008-10-01
Completion
2008-12-01
First posted
2008-01-07
Last updated
2010-08-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00586963. Inclusion in this directory is not an endorsement.